Anpac Bio Medical Performance
| ANPCDelisted Stock | USD 4.37 0.20 4.38% |
The firm shows a Beta (market volatility) of -1.52, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Anpac Bio are expected to decrease by larger amounts. On the other hand, during market turmoil, Anpac Bio is expected to outperform it. Anpac Bio Medical right now shows a risk of 0.0%. Please confirm Anpac Bio Medical maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if Anpac Bio Medical will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Anpac Bio Medical has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Anpac Bio is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 9.3 M |
Anpac |
Anpac Bio Relative Risk vs. Return Landscape
If you would invest 437.00 in Anpac Bio Medical on September 3, 2024 and sell it today you would earn a total of 0.00 from holding Anpac Bio Medical or generate 0.0% return on investment over 90 days. Anpac Bio Medical is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Anpac, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Anpac Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Anpac Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Anpac Bio Medical, and traders can use it to determine the average amount a Anpac Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ANPC |
Based on monthly moving average Anpac Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Anpac Bio by adding Anpac Bio to a well-diversified portfolio.
Anpac Bio Fundamentals Growth
Anpac Stock prices reflect investors' perceptions of the future prospects and financial health of Anpac Bio, and Anpac Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Anpac Stock performance.
| Return On Equity | -2.43 | |||
| Return On Asset | -0.53 | |||
| Operating Margin | (8.71) % | |||
| Current Valuation | 9.28 M | |||
| Shares Outstanding | 6.27 M | |||
| Price To Book | 5.67 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 12.04 M | |||
| EBITDA | (78.4 M) | |||
| Cash And Equivalents | 462 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 19.81 M | |||
| Debt To Equity | 1.44 % | |||
| Book Value Per Share | 10.63 X | |||
| Cash Flow From Operations | (55.06 M) | |||
| Earnings Per Share | (11.45) X | |||
| Total Asset | 40.47 M | |||
| Retained Earnings | (577.54 M) | |||
| Current Asset | 23.44 M | |||
| Current Liabilities | 68.22 M | |||
About Anpac Bio Performance
By analyzing Anpac Bio's fundamental ratios, stakeholders can gain valuable insights into Anpac Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Anpac Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Anpac Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the Peoples Republic of China. The company was incorporated in 2010 and is headquartered in Lishui, the Peoples Republic of China. Anpac Bio-Medical operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.Things to note about Anpac Bio Medical performance evaluation
Checking the ongoing alerts about Anpac Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Anpac Bio Medical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Anpac Bio Medical is not yet fully synchronised with the market data | |
| Anpac Bio Medical has a very high chance of going through financial distress in the upcoming years | |
| Anpac Bio Medical currently holds 19.81 M in liabilities with Debt to Equity (D/E) ratio of 1.44, which is about average as compared to similar companies. Anpac Bio Medical has a current ratio of 0.38, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Anpac Bio's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 12.04 M. Net Loss for the year was (103.6 M) with profit before overhead, payroll, taxes, and interest of 12.25 M. | |
| Anpac Bio Medical currently holds about 462 K in cash with (55.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. |
- Analyzing Anpac Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Anpac Bio's stock is overvalued or undervalued compared to its peers.
- Examining Anpac Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Anpac Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Anpac Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Anpac Bio's stock. These opinions can provide insight into Anpac Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Anpac Stock
If you are still planning to invest in Anpac Bio Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Anpac Bio's history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |